According to the congress report of the 14th annual meeting of the German Society of Nephrology, ten patients with severe ME/CFS underwent immunapheresis. In 7 out of 10 patients this leads to a significant improvement in symptoms. Prof. Dr. Scheibenbogen suspects an apheresis effect on the beta cell compartment, because autoantibodies against ß1 and ß2 receptors are significantly reduced.
A study, which is currently underway at the Charité, aims to clarify whether long-COVID patients also benefit from apheresis therapy. The titer of the anti-ß receptors serves as an indicator for this.